Replies to post #1712 on Ocera Therapeutics fka OCRX

[indunu]

I think they will. As it stands now, the TZYM pipeline has gone cold. Something caused the stock to tumble down from the $5 - $2
range, which lasted for a number of years, all of a sudden down through $1 to half that where it is now. One clinical failure did all that.

The merger brings the hope of these two related drugs for HE. A clinical study upcoming. A well credentialed new CEO and a rational plan.

As well, if the cold pipe line suddenly revives a bit with some new uses for the drug that failed in diabetes motility for use in non diabetic gi motility problems then that should be "icing" on the merger cake in TZYM's favor.

I am holding my shares with no plans to sell at this point. However, we all have to make that decision for ourselves